Have a personal or library account? Click to login
FEIBA prophylaxis in a patient with haemophilia and inhibitors Cover

FEIBA prophylaxis in a patient with haemophilia and inhibitors

By: Susan Hook  
Open Access
|Apr 2018

References

  1. 1. Srivastava A, Brewer AK, MauserSBunschoten EP et al. Treatment Guidelines Working Group. The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1V14.10.1111/j.1365-2516.2012.02909.x
  2. 2. Hilgartner MW, Makipernaa A, DiMichele DM. LongSterm FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261V8.10.1046/j.1365-2516.2003.00771.x
  3. 3. Valentino LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia 2006; 12TSuppl. 5U: 26V31.10.1111/j.1365-2516.2006.01382.x
  4. 4. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate TFEIBA©U reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249V55.10.1111/j.1365-2516.2007.01442.x
  5. 5. Leissinger C, Gringeri A, Antmen B et al. AntiSinhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684V92.10.1056/NEJMoa1104435
  6. 6. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and onSdemand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65S72.10.1111/hae.12246
  7. 7. Hoots WK, Ebbesen LS, Konkle BA et al, Novoseven TF7HAEMS1505U Investigators. Secondary prophylaxis with recombinant activated factor VII improves healthS related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466V75.10.1111/j.1365-2516.2008.01654.x
  8. 8. Ekert H, Brewin T, Boey W, et al. CostSutility analysis of recombinant factor VIIa TNovoSevenU in six children with longSstanding inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279V85.10.1046/j.1365-2516.2001.00502.x
  9. 9. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154V62.10.1111/j.1365-2516.2006.01204.x
  10. 10. van Genderen FR, van Meeteren NL, van der Bom JG, Heijnen L, De KP, van den Berg HM, et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia 2004; 10T5U: 565S71.10.1111/j.1365-2516.2004.01016.x
  11. 11. Groen WG, van der Net J, Helders PJ, Fischer K. Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List TPedHALU. Haemophilia 2010; 16: 281S9.10.1111/j.1365-2516.2009.02136.x
  12. 12. Groen W, Van Der Net J, Lacatusu AM, Serban M, et al. Functional limitations in Romanian children with haemophilia; further testing of psychometric properties of the Paediatric Haemophilia Activities List. Haemophilia 2103; 19: e116S125.10.1111/hae.12090
DOI: https://doi.org/10.17225/jhp.00031 | Journal eISSN: 2055-3390
Language: English
Page range: 21 - 23
Published on: Apr 21, 2018
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2018 Susan Hook, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.